262 related articles for article (PubMed ID: 23811282)
1. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.
Haasbach E; Reiling SJ; Ehrhardt C; Droebner K; Rückle A; Hrincius ER; Leban J; Strobl S; Vitt D; Ludwig S; Planz O
Antiviral Res; 2013 Sep; 99(3):336-44. PubMed ID: 23811282
[TBL] [Abstract][Full Text] [Related]
2. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity.
Mazur I; Wurzer WJ; Ehrhardt C; Pleschka S; Puthavathana P; Silberzahn T; Wolff T; Planz O; Ludwig S
Cell Microbiol; 2007 Jul; 9(7):1683-94. PubMed ID: 17324159
[TBL] [Abstract][Full Text] [Related]
3. The NF-κB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance.
Ehrhardt C; Rückle A; Hrincius ER; Haasbach E; Anhlan D; Ahmann K; Banning C; Reiling SJ; Kühn J; Strobl S; Vitt D; Leban J; Planz O; Ludwig S
Cell Microbiol; 2013 Jul; 15(7):1198-211. PubMed ID: 23320394
[TBL] [Abstract][Full Text] [Related]
4. Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo.
Haasbach E; Droebner K; Vogel AB; Planz O
J Interferon Cytokine Res; 2011 Jun; 31(6):515-25. PubMed ID: 21323570
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Haasbach E; Pauli EK; Spranger R; Mitzner D; Schubert U; Kircheis R; Planz O
Antiviral Res; 2011 Sep; 91(3):304-13. PubMed ID: 21777621
[TBL] [Abstract][Full Text] [Related]
6. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Ikematsu H; Kawai N
Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
[TBL] [Abstract][Full Text] [Related]
7. H7N9 and other pathogenic avian influenza viruses elicit a three-pronged transcriptomic signature that is reminiscent of 1918 influenza virus and is associated with lethal outcome in mice.
Morrison J; Josset L; Tchitchek N; Chang J; Belser JA; Swayne DE; Pantin-Jackwood MJ; Tumpey TM; Katze MG
J Virol; 2014 Sep; 88(18):10556-68. PubMed ID: 24991006
[TBL] [Abstract][Full Text] [Related]
8. 2009 pandemic H1N1 influenza A virus strains display differential pathogenicity in C57BL/6J but not BALB/c mice.
Otte A; Gabriel G
Virulence; 2011; 2(6):563-6. PubMed ID: 22030859
[TBL] [Abstract][Full Text] [Related]
9. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance.
Ehrhardt C; Hrincius ER; Korte V; Mazur I; Droebner K; Poetter A; Dreschers S; Schmolke M; Planz O; Ludwig S
Antiviral Res; 2007 Oct; 76(1):38-47. PubMed ID: 17572513
[TBL] [Abstract][Full Text] [Related]
10. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses.
Belser JA; Szretter KJ; Katz JM; Tumpey TM
Adv Virus Res; 2009; 73():55-97. PubMed ID: 19695381
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors of the c-Jun N-terminal kinase (JNK) possess antiviral activity against highly pathogenic avian and human pandemic influenza A viruses.
Nacken W; Ehrhardt C; Ludwig S
Biol Chem; 2012 May; 393(6):525-34. PubMed ID: 22628315
[TBL] [Abstract][Full Text] [Related]
12. Outbreak of highly pathogenic avian influenza in Japan and anti-influenza virus activity of povidone-iodine products.
Ito H; Ito T; Hikida M; Yashiro J; Otsuka A; Kida H; Otsuki K
Dermatology; 2006; 212 Suppl 1():115-8. PubMed ID: 16490988
[TBL] [Abstract][Full Text] [Related]
13. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro.
Lee SM; Gai WW; Cheung TK; Peiris JS
Antiviral Res; 2011 Sep; 91(3):330-4. PubMed ID: 21798291
[TBL] [Abstract][Full Text] [Related]
14. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.
Lackenby A; Democratis J; Siqueira MM; Zambon MC
Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
[TBL] [Abstract][Full Text] [Related]
16. Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza.
Zhao H; To KKW; Chu H; Ding Q; Zhao X; Li C; Shuai H; Yuan S; Zhou J; Kok KH; Jiang S; Yuen KY
Nat Commun; 2018 Jun; 9(1):2358. PubMed ID: 29907765
[TBL] [Abstract][Full Text] [Related]
17. [Current situation in human infections with highly pathogenic avian influenza viruses].
Obuchi M; Tashiro M
Nihon Rinsho; 2010 Sep; 68(9):1729-35. PubMed ID: 20845756
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.
Kumaki Y; Day CW; Smee DF; Morrey JD; Barnard DL
Antiviral Res; 2011 Nov; 92(2):329-40. PubMed ID: 21925541
[TBL] [Abstract][Full Text] [Related]
19. Emerging influenza.
de Wit E; Fouchier RA
J Clin Virol; 2008 Jan; 41(1):1-6. PubMed ID: 18340670
[TBL] [Abstract][Full Text] [Related]
20. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV).
Pleschka S; Stein M; Schoop R; Hudson JB
Virol J; 2009 Nov; 6():197. PubMed ID: 19912623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
